Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Prostatic Neoplasms 3Prostate Cancer Metastatic 2Myasthenia Gravis 2Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Subcutaneous panniculitis-like T-cell lymphoma 1Skin Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Pneumonia 1Pituitary Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Dementia 1Craniopharyngioma 1Cognitive Dysfunction 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Adrenal Insufficiency 1

Interventions

telitacicept 1Valsartan 1Pyridostigmine Bromide 1Prednisone 1Infliximab 1Hydroxychloroquine 1Etanercept 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Autoimmune Diseases × Prednisone × Clear all
NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase 4 Not yet recruiting
30 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡